Search Results - "Clapp, Lucie"

Refine Results
  1. 1

    The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors by Clapp, Lucie H., Gurung, Rijan

    Published in Prostaglandins & other lipid mediators (01-07-2015)
    “…Pulmonary arterial hypertension (PAH) is a progressive disease of distal pulmonary arteries in which patients suffer from elevated pulmonary arterial pressure,…”
    Get full text
    Journal Article
  2. 2

    Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: Treprostinil is a potent DP1 and EP2 agonist by Whittle, Brendan J., Silverstein, Adam M., Mottola, David M., Clapp, Lucie H.

    Published in Biochemical pharmacology (01-07-2012)
    “…Differential activation of human prostanoid receptors expressed in cells: EC50 values for prostacyclin analogues treprostinil or iloprost in stimulating…”
    Get full text
    Journal Article
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7

    Vasopressin: Mechanisms of action on the vasculature in health and in septic shock by Barrett, Lucinda K, Singer, Mervyn, Clapp, Lucie H

    Published in Critical care medicine (01-01-2007)
    “…BACKGROUND:Vasopressin is essential for cardiovascular homeostasis, acting via the kidney to regulate water resorption, on the vasculature to regulate smooth…”
    Get full text
    Journal Article
  8. 8

    Exploring the enzymatic degradation of poly(glycerol adipate) by Swainson, Sadie M.E., Taresco, Vincenzo, Pearce, Amanda K., Clapp, Lucie H., Ager, Barry, McAllister, Mark, Bosquillon, Cynthia, Garnett, Martin C.

    “…[Display omitted] Poly(glycerol adipate) (PGA) is a biodegradable, biocompatible, polymer with a great deal of potential in the field of drug delivery. Active…”
    Get full text
    Journal Article
  9. 9

    Smooth Muscle Proliferation and Role of the Prostacyclin (IP) Receptor in Idiopathic Pulmonary Arterial Hypertension by FALCETTI, Emilia, HALL, Susan M, PHILLIPS, Peter G, PATEL, Jigisha, MORRELL, Nicholas W, HAWORTH, Sheila G, CLAPP, Lucie H

    “…Prostacyclin analogs, used to treat idiopathic pulmonary arterial hypertension (IPAH), are assumed to work through prostacyclin (IP) receptors linked to cyclic…”
    Get full text
    Journal Article
  10. 10

    Relative Recovery of Non-Alcoholic Fatty Liver Disease (NAFLD) in Diet-Induced Obese Rats by Aboujassoum, Hamda M, Mohamed-Ali, Vidya, Abraham, David, Clapp, Lucie H, Al-Naemi, Hamda A

    Published in Nutrients (28-12-2023)
    “…Consumption of a high-carbohydrate diet has a critical role in the induction of weight gain and obesity-related pathologies. This study tested the hypothesis…”
    Get full text
    Journal Article
  11. 11

    Prostacyclin mimetics inhibit DRP1-mediated pro-proliferative mitochondrial fragmentation in pulmonary arterial hypertension by Abu-Hanna, Jeries, Anastasakis, Evangelos, Patel, Jigisha A., Eddama, Mohammad Mahmoud Rajab, Denton, Christopher P., Taanman, Jan-Willem, Abraham, David, Clapp, Lucie H.

    Published in Vascular pharmacology (01-08-2023)
    “…Pulmonary arterial hypertension (PAH) is a rare cardiopulmonary disorder, involving the remodelling of the small pulmonary arteries. Underlying this…”
    Get full text
    Journal Article
  12. 12

    Altered cyclooxygenase-1 and enhanced thromboxane receptor activities underlie attenuated endothelial dilatory capacity of omental arteries in obesity by Raees, Asmaa, Bakhamis, Aysha, Mohamed-Ali, Vidya, Bashah, Moataz, Al-Jaber, Mashael, Abraham, David, Clapp, Lucie H., Orie, Nelson N.

    Published in Life sciences (1973) (15-12-2019)
    “…Obesity is a risk factor for endothelial dysfunction, the severity of which is likely to vary depending on extent and impact of adiposity on the vasculature…”
    Get full text
    Journal Article
  13. 13

    Bronchodilation induced by PGE2 is impaired in Group III pulmonary hypertension by Ozen, Gulsev, Benyahia, Chabha, Mani, Salma, Boukais, Kamel, Silverstein, Adam M., Bayles, Richard, Nelsen, Andrew C., Castier, Yves, Danel, Claire, Mal, Hervé, Clapp, Lucie H., Longrois, Dan, Norel, Xavier

    Published in British journal of pharmacology (01-01-2020)
    “…Background and Purpose In patients with pulmonary hypertension (PH) associated with lung disease and/or hypoxia (Group III), decreased pulmonary vascular tone…”
    Get full text
    Journal Article
  14. 14

    Therapeutic potential of inhibiting histone 3 lysine 27 demethylases: a review of the literature by Abu-Hanna, Jeries, Patel, Jigisha A, Anastasakis, Evangelos, Cohen, Richard, Clapp, Lucie H, Loizidou, Marilena, Eddama, Mohammad M. R

    Published in Clinical epigenetics (01-08-2022)
    “…Abstract Histone 3 lysine 27 (H3K27) demethylation constitutes an important epigenetic mechanism of gene activation. It is mediated by the Jumonji C…”
    Get full text
    Journal Article
  15. 15

    Pharmacology of the single isomer, esuberaprost (beraprost-314d) on pulmonary vascular tone, IP receptors and human smooth muscle proliferation in pulmonary hypertension by Shen, Lei, Patel, Jigisha A., Norel, Xavier, Moledina, Shahin, Whittle, Brendan J., von Kessler, Kirby, Sista, Prakash, Clapp, Lucie H.

    Published in Biochemical pharmacology (01-08-2019)
    “…[Display omitted] Beraprost is a prostacyclin analogue and IP receptor agonist which is approved to treat pulmonary arterial hypertension (PAH) in Asia. The…”
    Get full text
    Journal Article
  16. 16

    Inhibition of Phosphodiesterase 2 Augments cGMP and cAMP Signaling to Ameliorate Pulmonary Hypertension by Bubb, Kristen J, Trinder, Sarah L, Baliga, Reshma S, Patel, Jigisha, Clapp, Lucie H, MacAllister, Raymond J, Hobbs, Adrian J

    Published in Circulation (New York, N.Y.) (05-08-2014)
    “…BACKGROUND—Pulmonary hypertension (PH) is a life-threatening disorder characterized by increased pulmonary artery pressure, remodeling of the pulmonary…”
    Get full text
    Journal Article
  17. 17

    The Prostacyclin Analogue, Treprostinil, Used in the Treatment of Pulmonary Arterial Hypertension, is a Potent Antagonist of TREK-1 and TREK-2 Potassium Channels by Cunningham, Kevin P., Clapp, Lucie H., Mathie, Alistair, Veale, Emma L.

    Published in Frontiers in pharmacology (29-06-2021)
    “…Pulmonary arterial hypertension (PAH) is an aggressive vascular remodeling disease that carries a high morbidity and mortality rate. Treprostinil (Remodulin)…”
    Get full text
    Journal Article
  18. 18

    Bronchodilation induced by PGE 2 is impaired in Group III pulmonary hypertension by Ozen, Gulsev, Benyahia, Chabha, Mani, Salma, Boukais, Kamel, Silverstein, Adam M, Bayles, Richard, Nelsen, Andrew C, Castier, Yves, Danel, Claire, Mal, Hervé, Clapp, Lucie H, Longrois, Dan, Norel, Xavier

    Published in British journal of pharmacology (01-01-2020)
    “…In patients with pulmonary hypertension (PH) associated with lung disease and/or hypoxia (Group III), decreased pulmonary vascular tone and tissue hypoxia is…”
    Get full text
    Journal Article
  19. 19

    Role of prostanoid IP and EP receptors in mediating vasorelaxant responses to PGI₂ analogues in rat tail artery: Evidence for Gᵢ/ₒ modulation via EP₃ receptors by Orie, Nelson N, Clapp, Lucie H

    Published in European journal of pharmacology (11-03-2011)
    “…Prostanoid IP receptors coupled to Gs are thought to be the primary target for prostacyclin (PGI₂) analogues. However, these agents also activate prostanoid…”
    Get full text
    Journal Article
  20. 20